Related Experiment Video
Updated: Jan 11, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Integrative Strategies to Enhance Enzyme-Protein Interactions for Drug Discovery and Biocatalysis
R Satheeskumar1, V Premalatha2, M Navaneetha Krishnan3
1Narasaraopeta Engineering College, Narasaraopet, Andhra Pradesh, India. satheesme@gmail.com.
We developed a hybrid computational-experimental platform to precisely modulate enzyme-protein interactions (EPIs), significantly reducing false positives and costs in drug discovery and biocatalysis.
Area of Science:
- Biochemistry
- Computational Biology
- Drug Discovery
Background:
- Enzyme-protein interactions (EPIs) are crucial for drug development and industrial processes.
- Conventional screening methods suffer from high false-positive rates (20-30%) and limited computational accuracy.
- Accurate modulation of EPIs is essential for advancing pharmaceutical and biotechnological applications.
Purpose of the Study:
- To develop an integrated computational and experimental platform for precise modulation of enzyme-protein interactions (EPIs).
- To overcome the limitations of conventional screening methods, including high false-positive rates and low predictive accuracy.
- To demonstrate the platform's efficacy in both therapeutic drug discovery and industrial biocatalysis.
Main Methods:
- Integration of advanced computational modeling (molecular docking, MD simulations, QM/MM) with machine learning for candidate prioritization.
- Utilization of high-precision experimental validation techniques such as Förster/BRET and Surface Plasmon Resonance (SPR).
- Application of structure-guided engineering and open-source computational tools (GROMACS, AutoDock Vina).
Main Results:
- Achieved high correlation between predicted binding energies (ΔG = -8 to -10 kcal/mol) and experimental dissociation constants (K_D = 100-500 nM).
- Enhanced target specificity by 40% and reduced off-target effects by 30% (p < 0.01).
- Demonstrated therapeutic potential with BRAF V600E inhibitors (EC50 = 11 nM) causing 45% tumor regression; boosted biofuel and L-lysine yields by 35% and 28% respectively.
Conclusions:
- The hybrid platform offers a versatile and accurate solution for precision EPI modulation.
- Significantly reduced screening false positives to <5%, shortened development timelines by 20%, and cut production costs by 18.6%.
- The framework holds transformative potential for accelerating drug discovery and enabling sustainable manufacturing processes.
More Related Videos
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Protein-protein Interfaces
Introduction to Mechanisms of Enzyme Catalysis
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Bioavailability Enhancement: Drug Permeability Enhancement
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...